Oruka Therapeutics, Inc. ORKA Accretion (Amortization) of Discounts and Premiums, Investments
Accretion (Amortization) of Discounts and Premiums, Investments at other companies
Other financials
Where this comes from
Reported directly by Oruka Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments.
The official record: Oruka Therapeutics, Inc.’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →
Ask your AI about Oruka Therapeutics, Inc.'s accretion (amortization) of discounts and premiums, investments.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Oruka Therapeutics, Inc.'s accretion (amortization) of discounts and premiums, investments?
- Oruka Therapeutics, Inc. (ORKA) reported accretion (amortization) of discounts and premiums, investments of $446K in Q1 2026.
- How has Oruka Therapeutics, Inc.'s accretion (amortization) of discounts and premiums, investments changed year-over-year?
- Oruka Therapeutics, Inc.'s accretion (amortization) of discounts and premiums, investments decreased by 75.2% year-over-year, from $1.8M to $446K.
- What does accretion (amortization) of discounts and premiums, investments mean?
- This represents the non-cash adjustment to the carrying value of investment securities due to the amortization of premiums or accretion of discounts over the life of the instrument. It reconciles the difference between the purchase price and the face value of debt securities held as investments. This adjustment is necessary to reflect the effective interest income earned on the investment portfolio.